A drug currently in phase 2 clinical trials for COPD and Asthma maybe effective for the treatment of Cystic Fibrosis. Verona Pharma is expected to present some data at the upcoming NACFC on their drug called RPL554, which they claim will help "activate" the CFTR protein. CFTR activation may also contribute to the efficacy of inhaled RPL554 already observed in COPD and asthma. There is no data yet on what exactly is meant by "Activation" and if this would result in any significant lung function improvement.
There is no published work yet, but a manuscript describing the full results from these studies is being prepared for publication by the end of 2014 in an appropriate peer-reviewed scientific journal.
Verona Pharma stock rose 19% on the news, so investors are excited. That could be a sign of positive results if they did their due diligence.
Source: http://www.stockmarketwire.com/article/4893533/VRPs-RPL554-update.html
Like, share and comment on our Facebook: https://www.facebook.com/knowcf/posts/10152848314873777
- Chris
There is no published work yet, but a manuscript describing the full results from these studies is being prepared for publication by the end of 2014 in an appropriate peer-reviewed scientific journal.
Verona Pharma stock rose 19% on the news, so investors are excited. That could be a sign of positive results if they did their due diligence.
Source: http://www.stockmarketwire.com/article/4893533/VRPs-RPL554-update.html
Like, share and comment on our Facebook: https://www.facebook.com/knowcf/posts/10152848314873777
- Chris